These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 952530)

  • 1. Corticosteroid-induced cutaneous atrophy and telangiectasia. Experimental production associated with weight loss in rats.
    Smith JG; Wehr RF; Chalker DK
    Arch Dermatol; 1976 Aug; 112(8):1115-7. PubMed ID: 952530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle.
    Gans EH; Sadiq I; Stoudemayer T; Stoudemayer M; Kligman AM
    J Drugs Dermatol; 2008 Jan; 7(1):28-32. PubMed ID: 18246695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
    Serup J; Holm P
    Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of atrophy of human skin caused by corticosteroids using chamber occlusion and suction blister techniques.
    Somerma S; Lassus A; Salde L
    Acta Derm Venereol; 1984; 64(1):41-5. PubMed ID: 6203280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical corticosteroids.
    Pace WE
    Can Med Assoc J; 1973 Jan; 108(1):ll passim. PubMed ID: 4682644
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative evaluation of skin atrophy in man induced by topical corticoids.
    Jablonska S; Groniowska M; Dabroswki J
    Br J Dermatol; 1979 Feb; 100(2):193-206. PubMed ID: 154921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adrenocortical suppression by topically applied corticosteroids in healthy dogs.
    Zenoble RD; Kemppainen RJ
    J Am Vet Med Assoc; 1987 Sep; 191(6):685-8. PubMed ID: 2824410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroid-induced atrophy of the skin with telangiectasia. A clinical and experimental study.
    Stevanović DV
    Br J Dermatol; 1972 Dec; 87(6):548-56. PubMed ID: 4648801
    [No Abstract]   [Full Text] [Related]  

  • 9. A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses.
    Uliasz A; Zeichner J; Soung J; Wong V; Lebwohl M
    Cutis; 2008 Jun; 81(6):517-9. PubMed ID: 18666395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical corticosteroids for skin disorders.
    Med Lett Drugs Ther; 1966 May; 8(10):37-8. PubMed ID: 4223426
    [No Abstract]   [Full Text] [Related]  

  • 11. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy.
    McMichael AJ; Griffiths CE; Talwar HS; Finkel LJ; Rafal ES; Hamilton TA; Voorhees JJ
    Br J Dermatol; 1996 Jul; 135(1):60-4. PubMed ID: 8776360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proceedings: Measurement of dermal atrophy induced by topical steroids using a radiographic technique.
    James MP; Black MM; Sparkes CG
    Br J Dermatol; 1976 Jul; 95 Suppl 14():12. PubMed ID: 1276038
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hypotrophic effect of topical corticosteroids on cutaneous connective tissue (author's transl)].
    Weirich EG; Longauer J
    Res Exp Med (Berl); 1974 Jul; 163(3):229-39. PubMed ID: 4603591
    [No Abstract]   [Full Text] [Related]  

  • 14. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
    Rigopoulos D; Ioannides D; Kalogeromitros D; Gregoriou S; Katsambas A
    Br J Dermatol; 2004 Nov; 151(5):1071-5. PubMed ID: 15541087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiinflammatory activity and thymolytic effect of a new corticosteroid ester (I.S.F. 2073) by topical application.
    Banfi S; Cornelli U; Carpi C
    Curr Ther Res Clin Exp; 1976 Jan; 19(1):126-32. PubMed ID: 812657
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of synemol cream and other topical corticosteroid creams using the vasoconstrictor bioassay.
    Strand LJ; Flatman CJ; Northway CS; Evans CD
    Cutis; 1977 May; 19(5):689-91. PubMed ID: 862429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. THE USE AND ABUSE OF TOPICAL STEROID THERAPY.
    WRONG NM
    Can Med Assoc J; 1965 Jun; 92(25):1309-10. PubMed ID: 14291460
    [No Abstract]   [Full Text] [Related]  

  • 18. Double-blind clinical trial comparing fluocinonide FAPG cream with flumethasone pivalate cream.
    Baran R
    Acta Derm Venereol Suppl (Stockh); 1971 May; 52(67):79-81. PubMed ID: 5291638
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
    Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
    Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development and regression of dermal corticosteroid atrophy. 1. Change in the skinfold thickness].
    Lubach D; Hinz E
    Derm Beruf Umwelt; 1986; 34(5):146-9. PubMed ID: 2947794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.